Medical Imaging (6637) reported revenue of NT$120.6 million for Oct 2026, +107.1% year on year and +5.5% from the previous month. Revenue for Jan–Oct 2026 was NT$849.1 million (-12.7% year on year).
Year-on-year revenue growth: 3 months in a row. →
In Oct 2026, it ranked No. 65 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$120.6 million | +107.1% | +5.5% |
| Sep 2026 | NT$114.3 million | +141.6% | +163.7% |
| Aug 2026 | NT$43.3 million | +0.9% | -14.0% |
| Jul 2026 | NT$50.4 million | -8.6% | -78.9% |
| Jun 2026 | NT$238.7 million | +300.8% | +406.9% |
| May 2026 | NT$47.1 million | -91.0% | +4.4% |
| Apr 2026 | NT$45.1 million | -24.2% | -14.5% |
| Mar 2026 | NT$52.7 million | +19.1% | -43.7% |
| Feb 2026 | NT$93.7 million | +196.3% | +117.1% |
| Jan 2026 | NT$43.2 million | -11.9% | -71.5% |
| Dec 2025 | NT$151.3 million | +175.7% | +278.7% |
| Nov 2025 | NT$40 million | -26.2% | -31.4% |
| Oct 2025 | NT$58.2 million | -43.0% | +23.1% |
| Sep 2025 | NT$47.3 million | -64.3% | +10.1% |
| Aug 2025 | NT$42.9 million | -12.0% | -22.1% |
| Jul 2025 | NT$55.1 million | -9.2% | -7.4% |
| Jun 2025 | NT$59.6 million | +26.8% | -88.7% |
| May 2025 | NT$525.6 million | +955.9% | +783.3% |
| Apr 2025 | NT$59.5 million | -46.5% | +34.4% |
| Mar 2025 | NT$44.3 million | -20.8% | +40.0% |
| Feb 2025 | NT$31.6 million | -25.8% | -35.5% |
| Jan 2025 | NT$49 million | -31.1% | -10.7% |
| Dec 2024 | NT$54.9 million | -55.9% | +1.3% |
| Nov 2024 | NT$54.2 million | -25.7% | -46.9% |
| Oct 2024 | NT$102.1 million | +148.9% | -22.8% |
Jan–Oct 2026 cumulative: NT$849.1 million (-12.7% YoY)
Other Biotech & Medical companies
Compare with peers: Medical Imaging vs PEC / Medical Imaging vs Lotus Pharm / Medical Imaging vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
主因本月醫療儀器設備銷售收入較去年同期為高。
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16